chlorthalidone has been researched along with Renal Insufficiency, Chronic in 24 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Renal Insufficiency, Chronic: Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 9.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "We randomly assigned patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12." | 9.41 | Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Dickinson, JH; Ouyang, F; Sinha, AD; Tu, W, 2021) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 5.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "We randomly assigned patients with stage 4 chronic kidney disease and poorly controlled hypertension, as confirmed by 24-hour ambulatory blood-pressure monitoring, in a 1:1 ratio to receive chlorthalidone at an initial dose of 12." | 5.41 | Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Dickinson, JH; Ouyang, F; Sinha, AD; Tu, W, 2021) |
| "Chlorthalidone in Chronic Kidney Disease (CLICK) is a phase II, single-institution, multicenter, double-blind randomized control trial to test the hypothesis that CTD improves BP, through reduction of extracellular fluid volume, and results in target organ protection in patients with stage 4 CKD and poorly controlled hypertension." | 5.34 | Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial. ( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Ouyang, F; Sinha, AD; Tu, W, 2020) |
| "Enablement of more persistent spironolactone use with newer potassium-binding agents, the clinical development of novel nonsteroidal MRAs with a more favourable benefit-risk profile and the recently proven blood pressure lowering action of chlorthalidone are three therapeutic opportunities for more effective management of hypertension in high-risk patients with advanced CKD." | 5.22 | Management of hypertension in advanced kidney disease. ( Agarwal, R; Georgianos, PI, 2022) |
| "Recent evidence supports expanded indications for diuretics in patients with kidney disease, including chlorthalidone for hypertension in advanced CKD." | 5.22 | Revisiting diuretic choice in chronic kidney disease. ( Ali, S; Gregg, LP; Navaneethan, SD; Virani, SS, 2022) |
| "This cohort study found that among older adults, chlorthalidone use was associated with a higher risk of eGFR decline, cardiovascular events, and hypokalemia compared with hydrochlorothiazide use." | 4.02 | Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. ( Bugeja, A; Burns, K; Canney, M; Edwards, C; Hundemer, GL; Knoll, G; Petrcich, W; Sood, MM, 2021) |
| "For patients with treatment-resistant hypertension, guidelines recommend the addition of spironolactone to the baseline antihypertensive regimen." | 3.01 | Hypertension in chronic kidney disease-treatment standard 2023. ( Agarwal, R; Georgianos, PI, 2023) |
| " AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ." | 2.87 | Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. ( Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (20.83) | 24.3611 |
| 2020's | 19 (79.17) | 2.80 |
| Authors | Studies |
|---|---|
| Edwards, C | 1 |
| Hundemer, GL | 1 |
| Petrcich, W | 1 |
| Canney, M | 1 |
| Knoll, G | 1 |
| Burns, K | 1 |
| Bugeja, A | 1 |
| Sood, MM | 1 |
| Agarwal, R | 8 |
| Sinha, AD | 5 |
| Cramer, AE | 2 |
| Balmes-Fenwick, M | 2 |
| Dickinson, JH | 1 |
| Ouyang, F | 2 |
| Tu, W | 4 |
| Allison, SJ | 1 |
| Wheeler, DC | 1 |
| Crews, DC | 1 |
| Lindner, G | 1 |
| Ravioli, S | 1 |
| Elias, R | 1 |
| Zatz, R | 1 |
| Afsar, B | 1 |
| Kanbay, M | 1 |
| Elsurer Afsar, R | 1 |
| Furgeson, SB | 1 |
| Linas, S | 1 |
| Georgianos, PI | 2 |
| Ali, S | 1 |
| Navaneethan, SD | 1 |
| Virani, SS | 1 |
| Gregg, LP | 1 |
| Kunz, M | 1 |
| Götzinger, F | 1 |
| Emrich, I | 1 |
| Schwenger, V | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Solis-Jimenez, F | 1 |
| Perez-Navarro, LM | 1 |
| Cabrera-Barron, R | 1 |
| Chida-Romero, JA | 1 |
| Martin-Alemañy, G | 1 |
| Dehesa-López, E | 1 |
| Madero, M | 1 |
| Valdez-Ortiz, R | 1 |
| van der Giet, M | 1 |
| Nitschmann, S | 1 |
| van der Merwe, WM | 1 |
| Bakris, GL | 1 |
| Zhao, L | 1 |
| Kupfer, S | 1 |
| Juhasz, A | 1 |
| Hisada, M | 1 |
| Lloyd, E | 1 |
| Oparil, S | 2 |
| Pappas, MK | 1 |
| Ammous, F | 1 |
| Whittle, J | 1 |
| Lynch, AI | 1 |
| Tanner, RM | 1 |
| Simpson, LM | 1 |
| Davis, BR | 1 |
| Rahman, M | 1 |
| Whelton, PK | 1 |
| Muntner, P | 1 |
| Karadsheh, F | 1 |
| Weir, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02841280] | Phase 2 | 160 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828] | Phase 3 | 153 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease[NCT02875886] | Phase 4 | 28 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Chlorthalidone | -11.0 |
| Placebo | -0.5 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | Liters (Mean) | ||
|---|---|---|---|
| Change in body volume 4 weeks from baseline | Change in body volume 8 weeks from baseline | Change in body volume 12 weeks from baseline | |
| Chlorthalidone | -1.1 | -1.7 | -2 |
| Placebo | 0.2 | 0.3 | 0.3 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change (Geometric Mean) | |||||
|---|---|---|---|---|---|---|
| Percent change 4 weeks from baseline in aldosterone | Percent change 8 weeks from baseline in aldosterone | Percent change 12 weeks from baseline in aldosterone | Percent change 4 weeks from baseline in renin | Percent change 8 weeks from baseline in renin | Percent change 12 weeks from baseline in renin | |
| Chlorthalidone | 57 | 65 | 52 | 57 | 67 | 64 |
| Placebo | 16 | 12 | 8 | 14 | 5 | 15 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change in NTproBNP (Geometric Mean) | ||
|---|---|---|---|
| Percent change from 4 weeks from baseline in NTproBNP | Percent change from 8 weeks from baseline in NTproBNP | Percent change from 12 weeks from baseline in NTproBNP | |
| Chlorthalidone | -25 | -32 | -30 |
| Placebo | -14 | 5 | -11 |
(NCT02841280)
Timeframe: Baseline to 12 weeks
| Intervention | percentage of change in UACR (Mean) | ||
|---|---|---|---|
| Percent change in albuminuria 4 weeks from baseline in UACR | Percent change in albuminuria 8 weeks from baseline in UACR | Percent change in albuminuria 12 weeks from baseline in UACR | |
| Chlorthalidone | -41 | -45 | -52 |
| Placebo | -7 | -3 | -4 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 69.3 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 78.4 |
Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 58.7 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 73.0 |
Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Azilsartan Medoxomil + Chlorthalidone | 80.0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 87.8 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Adverse Events | Adverse Events Leading to Discontinuation | Serious Adverse Events | Serious Adverse Events Leading to Discontinuation | Death | |
| Azilsartan Medoxomil + Chlorthalidone | 68 | 17 | 8 | 5 | 0 |
| Olmesartan Medoxomil + Hydrochlorothiazide | 58 | 15 | 9 | 4 | 1 |
5 reviews available for chlorthalidone and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Management of hypertension in advanced kidney disease.
Topics: Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineralocorticoid Receptor Antag | 2022 |
Revisiting diuretic choice in chronic kidney disease.
Topics: Acute Kidney Injury; Chlorthalidone; Diuretics; Humans; Hypertension; Renal Insufficiency, Chronic; | 2022 |
Cardio-renal interaction - Clinical trials update 2022.
Topics: Chlorthalidone; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucose; Humans; Kidney; Minera | 2022 |
Hypertension in chronic kidney disease-treatment standard 2023.
Topics: Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hyperkalemia; Hypertension; Mineral | 2023 |
Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease.
Topics: Antihypertensive Agents; Chlorthalidone; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Hy | 2012 |
5 trials available for chlorthalidone and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease.
Topics: Aged; Albuminuria; Blood Pressure; Chlorthalidone; Creatinine; Diuretics; Double-Blind Method; Femal | 2021 |
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.
Topics: Aged; Bumetanide; Chlorthalidone; Humans; Hypertension; Middle Aged; Renal Insufficiency, Chronic; R | 2022 |
Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chlorthalidone | 2020 |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Topics: Aged; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide | 2018 |
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlo | 2014 |
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlo | 2014 |
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlo | 2014 |
Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlo | 2014 |
14 other studies available for chlorthalidone and Renal Insufficiency, Chronic
| Article | Year |
|---|---|
Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function.
Topics: Aged; Chlorthalidone; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration | 2021 |
Chlorthalidone in advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Renal Insufficiency, Chronic | 2021 |
In advanced CKD with poorly controlled hypertension, chlorthalidone reduced BP at 12 wk.
Topics: Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Hypertension in Advanced CKD. Reply.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone and Advanced Chronic Kidney Disease.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
Chlorthalidone for Resistant Hypertension in Advanced Chronic Kidney Disease.
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2022 |
[Chlorthalidone in chronic kidney disease].
Topics: Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Renal Insufficiency, Chronic | 2023 |
Refractory Hypertension and Kidney Failure: Focusing on the Social Determinants of Health.
Topics: Chlorthalidone; Humans; Hypertension; Outcome Assessment, Health Care; Renal Insufficiency; Renal In | 2021 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; | 2018 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |